Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00420602 · ClinicalTrials.gov registry record · NA
DHA Supplementation in Patients With STGD3
A NA study, sponsored by University of Utah.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT00420602 is a NA study that has completed, run by University of Utah. The registered enrollment target is 11 participants.
The verdict
NCT00420602, a NA study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
We have found that biomarkers of long-term elevated dietary intake of omega-3 fatty acids such as DHA and EPA are inversely associated with severity of disease phenotype in STGD3 patients. Therefore, the purpose of this study is to follow STGD3 patients as they supplement their diets with DHA/EPA.
Interventions
- DIETARY_SUPPLEMENT Over the counter DHA/EPA dietary supplementation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-09-21 |
| Est. Completion | 2017-12-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00420602
The ClinicalTrials.gov registry entry for NCT00420602 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Over the counter DHA/EPA dietary supplementation is the first listed.
NCT00420602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00420602 about?
NCT00420602 is a clinical study titled "DHA Supplementation in Patients With STGD3". We have found that biomarkers of long-term elevated dietary intake of omega-3 fatty acids such as DHA and EPA are inversely associated with severity of disease phenotype in STGD3 patients. Therefore, the purpose of this study is to follow STGD3 patients as they supplement their diets with DHA/EPA.
What is the current status of trial NCT00420602?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2007-09-21. Estimated completion is 2017-12-27.
What interventions are being tested in trial NCT00420602?
The interventions under investigation include: Over the counter DHA/EPA dietary supplementation (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00420602?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.